Safety, Tolerability and Pharmacokinetics Study of KK - R002 in Healthy Adult Participants

INTERVENTION: Single‐dose administration study:Single intravenous infusion administration;Multiple‐dose studies:Multiple intravenous infusions for administration;Drug interaction research:Administer a single intravenous infusion per cycle; CONDITION: Bacterial infectious diseases PRIMARY OUTCOME: Pharmacokinetic indicators;Security Indicators; INCLUSION CRITERIA: 1.Healthy subjects aged 18 to 45 years (including the threshold); 2.Weight >=50.0 kg for men and>=45.0 kg for women; body mass inde X(BMI) within the range of 19.0 to 26.0 kg/m^2 (including threshold values); 3.Subjects (including male subjects) do not plan to have children and voluntarily use effective contraception during the trial period and within 3 months after the last dose, and do not plan to donate sperm or eggs; 4.The subject fully understands the purpose and nature of the trial, the trial procedure, and possible adverse effects, volunteers as a subject, can communicate well with the investigator, complies with the requirements of the entire study, and signs an informed consent form prior to the commencement of any study procedures.